Luminogenic cytochrome P450 assays (Q36543124)

14 August 2017

1 reference

title

Luminogenic cytochrome P450 assays (English)

1 reference

14 August 2017

James J Cali

1

1 reference

14 August 2017

Dongping Ma

2

1 reference

14 August 2017

Mary Sobol

3

1 reference

14 August 2017

Daniel J Simpson

4

1 reference

14 August 2017

Susan Frackman

5

1 reference

14 August 2017

Troy D Good

6

1 reference

14 August 2017

William J Daily

7

1 reference

14 August 2017

David Liu

8

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Expert Opinion on Drug Metabolism & Toxicology

14 August 2017

1 reference

14 August 2017

2

1 reference

14 August 2017

4

1 reference

14 August 2017

629-645

1 reference

The human hepatic cytochromes P450 involved in drug metabolism

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Human CYPs: in vivo and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Predicting in vivo drug interactions from in vitro drug discovery data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

High throughput P450 inhibition screens in early drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

The safety of newly approved medicines: do recent market removals mean there is a problem?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Cytochrome P450 enzymes in drug metabolism and chemical toxicology: An introduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Cell-based models to study hepatic drug metabolism and enzyme induction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

A fluorescent cell-based assay for cytochrome P-450 isozyme 1A2 induction and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

PXR, CAR and drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Differential regulation of human CYP4A genes by peroxisome proliferators and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Utility of recombinant cytochrome p450 enzymes: a drug metabolism perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Site-directed mutagenesis of histidine 245 in firefly luciferase: a proposed model of the active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Cooperativity in oxidations catalyzed by cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Induction of cytochrome P4501A1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Coumarin substrates for cytochrome P450 2D6 fluorescence assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Using IMAP technology to identify kinase inhibitors: comparison with a substrate depletion approach and analysis of the nature of false positives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

CYP3A4 drug interactions: correlation of 10 in vitro probe substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

In vitro and pharmacophore insights into CYP3A enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

Diclofenac and Its Derivatives As Tools for Studying Human Cytochromes P450 Active Sites: Particular Efficiency and Regioselectivity of P450 2Cs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.629

21 January 2018

Identifiers

DOI

10.1517/17425255.2.4.629

1 reference

14 August 2017

1 reference